{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-099382","form_type":"8-K","ticker":"ALKS","cik":"0001520262","company_name":"Alkermes plc.","filed_at":"2025-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.207389+00:00","generated_at":"2026-05-17T23:40:31.747583+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Alkermes Q2 revenue $390.7M, GAAP EPS $0.52; product sales grow 14% YoY","bullets":["Total Q2 revenues $390.7M (-2% YoY); GAAP net income $87.1M, diluted EPS $0.52.","Proprietary net sales $307.2M (+14% YoY): LYBALVI $84.3M (+18%), ARISTADA $101.3M (+18%), VIVITROL $121.7M (+9%).","Adjusted EBITDA $126.5M; cash & investments $1.05B at June 30, 2025.","Company reaffirms 2025 financial expectations.","R&D spend $77.4M (+30% YoY) on alixorexton; positive Vibrance-1 phase 2 results support global phase 3."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-099382","json":"https://secwatch.observer/filing/0000950170-25-099382.json","markdown":"https://secwatch.observer/filing/0000950170-25-099382.md","text":"https://secwatch.observer/filing/0000950170-25-099382.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1520262/000095017025099382/0000950170-25-099382-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1520262/000095017025099382/alks-20250729.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T23:40:31.747583+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}